Literature DB >> 25275024

The apelin-APJ system induces tumor arteriogenesis in hepatocellular carcinoma.

Jun Muto1, Ken Shirabe2, Tomoharu Yoshizumi3, Toru Ikegami3, Shinichi Aishima4, Kousei Ishigami5, Yoshikazu Yonemitsu6, Tetsuo Ikeda3, Yuji Soejima3, Yoshihiko Maehara3.   

Abstract

AIM: The apelin-APJ system regulates angiogenesis, and is overexpressed in several types of cancer. The aim of this study was to clarify the role of the apelin-APJ system in the angiogenesis of hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Expressions of angiogenic factors and vascular markers were investigated in specimens from 90 HCC patients. A subcutaneous HCC tumor mouse model was treated with the APJ antagonist, F13A, and tumor growth and vascular development were assessed.
RESULTS: APJ expression was observed in arteriole-smooth muscle. Higher amounts of APJ(+)-arteriole and apelin were detected in tumors (p<0.001 for both). APJ(+)-arteriole and apelin expression were more commonly observed in moderately- and poorly-differentiated than in well-differentiated HCC (p ≤ 0.003). HCC with irregular dilated arteries expressed higher levels of apelin (p=0.012). Tumor growth was inhibited by treatment with F13A (p<0.001), and arterioles were decreased in the treated group (p=0.047), in vivo.
CONCLUSION: Apelin-APJ is overexpressed, and works as a signal for arteriogenesis in HCC. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  APJ; Apelin; angiogenesis; arteriogenesis; hepatocellular carcinoma

Mesh:

Substances:

Year:  2014        PMID: 25275024

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

1.  Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.

Authors:  Chad Hall; Laurent Ehrlich; Julie Venter; April O'Brien; Tori White; Tianhao Zhou; Tien Dang; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Cancer Lett       Date:  2016-11-26       Impact factor: 8.679

2.  Evaluation of Apelin/APJ system expression in hepatocellular carcinoma as a function of clinical severity.

Authors:  Manuela Cabiati; Melania Gaggini; Paolo De Simone; Silvia Del Ry
Journal:  Clin Exp Med       Date:  2020-11-17       Impact factor: 3.984

3.  Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy.

Authors:  Li Zhang; Kazuhiro Takara; Daishi Yamakawa; Hiroyasu Kidoya; Nobuyuki Takakura
Journal:  Cancer Sci       Date:  2015-11-12       Impact factor: 6.716

Review 4.  The Role of the Apelin/APJ System in the Regulation of Liver Disease.

Authors:  Xinrui Lv; Jing Kong; Wei-Dong Chen; Yan-Dong Wang
Journal:  Front Pharmacol       Date:  2017-04-24       Impact factor: 5.810

Review 5.  The Role of Apelin in Cardiovascular Diseases, Obesity and Cancer.

Authors:  Marta B Wysocka; Katarzyna Pietraszek-Gremplewicz; Dorota Nowak
Journal:  Front Physiol       Date:  2018-05-23       Impact factor: 4.566

6.  APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.

Authors:  Huarong Chen; Chi-Chun Wong; Dabin Liu; Minnie Y Y Go; Bin Wu; Sui Peng; Ming Kuang; Nathalie Wong; Jun Yu
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

7.  Mechanism of KLF4 Protection against Acute Liver Injury via Inhibition of Apelin Signaling.

Authors:  Weitao Ji; Hongyun Shi; Hailin Shen; Jing Kong; Jiayi Song; Hongyan Bian; Xinrui Lv
Journal:  Oxid Med Cell Longev       Date:  2019-10-10       Impact factor: 6.543

8.  Apelin promotes hepatic fibrosis through ERK signaling in LX-2 cells.

Authors:  Ying Wang; Jiayi Song; Hongyan Bian; Jiaqi Bo; Shuangyu Lv; Weitong Pan; Xinrui Lv
Journal:  Mol Cell Biochem       Date:  2019-07-03       Impact factor: 3.396

Review 9.  Apelin/APJ system: A key therapeutic target for liver disease.

Authors:  Shuang-Yu Lv; Binbin Cui; Wei-Dong Chen; Yan-Dong Wang
Journal:  Oncotarget       Date:  2017-12-01

10.  Repurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization.

Authors:  Danielle McAnally; Khandaker Siddiquee; Ahmed Gomaa; Andras Szabo; Stefan Vasile; Patrick R Maloney; Daniela B Divlianska; Satyamaheshwar Peddibhotla; Camilo J Morfa; Paul Hershberger; Rebecca Falter; Robert Williamson; David B Terry; Rafal Farjo; Anthony B Pinkerton; Xiaping Qi; Judith Quigley; Michael E Boulton; Maria B Grant; Layton H Smith
Journal:  PLoS One       Date:  2018-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.